Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Okay. We'll go ahead and get started. This -- thanks, everyone, for attending here, the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Alnylam, and presenting on behalf of the company is CEO, John Maraganore. John?
Great. Well, thanks, Anupam. Joining me on the stage this morning are Pushkal Garg, our CMO; Barry Greene, our President; Yvonne Greenstreet, our COO; Jeff Poulton, our CFO; and Akshay Vaishnaw, our President of R&D.
Now 10 years ago on this stage, we suggested that the 2010s might be the RNA decade. Well, if you look at what happened to Alnylam over the last 10 years, we actually might have been right. We started the decade in 2010 as a company that was -- I think most people thought we weren't going to necessarily make it,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
